Multiplexing
Multiplexing is a technique that enables the simultaneous detection of various biomarkers in a single assay. By incorporating different fluorophores with distinct emission spectra and employing suitable detection methods, multiplexing enhances the throughput and efficiency of experiments. Our multiplexing technology is based on TR-FRET, a rapid, no-wash and low-interference technique.
The TR-FRET immunoassay is an analytical method employed for the detection and quantification of biomarkers present in serum, plasma and cell supernatant. Our Bright-Dtech™ fluorescent nanoparticles offer a more sensitive and stable approach. In the Bright-Dtech™ TR-FRET method, we engineer our nanoparticles and acceptors to detect various biomarkers with high specificity, sensitivity and cost-effectiveness.
In the multiplexing technology based on Bright-Dtech™, the nanoparticle can be coupled with two different biological entities to detect two distinct targets. Indeed, this principle involves one acceptor for each antigen detected.
Then, the fluorescent intensity of the donor antibody is transferred to the acceptor, and a signal is detected using time-resolved fluorescence reader. Standard curves, quantifying each biomarker studied through the multiplexing technology, can therefore be established.
Why using Bright-Dtech™ for multiplexing technology ?
Our Bright-Dtech™ technology offers more specific and sensitive detection with improved limits of detection (LOD) and limits of quantification (LOQ) and, its eliminates background noise due to the high-performance of fluorescent nanoaprticles.
Bright-Dtech™ also allows for cost reduction, requiring only a microplate reader with a TRF option.